Clinical development of valbenazine for tics associated with Tourette syndrome

References

• Billnitzer A, Jankovic J. Current management of tics and tourette syndrome: behavioral, pharmacologic, and surgical treatments. Neurotherapeutics. 2020 Aug 27;17(4):1681–1693.
   Web of Science ®Google Scholar
• Quezada J, Coffman KA. Current approaches and new developments in the pharmacological management of tourette syndrome. CNS Drugs. 2018 Jan;32(1):33–45.
   PubMed Web of Science ®Google Scholar
• Mittal SO. Tics and Tourette’s syndrome. Drugs Context. 2020;9:1–7.
   PubMedGoogle Scholar
• Diagnostic and statistical manual of mental disorders. 5th ed. Washington D.C.: American Psychiatric Association. 2013.
   Google Scholar
• Seideman MF, Seideman TA. A review of the current treatment of tourette syndrome. J Pediatr Pharmacol Ther. 2020;25(5):401–412.
   PubMedGoogle Scholar
• Hirschtritt ME, Lee PC, Pauls DL, et al. Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome. JAMA Psychiatry. 2015 Apr;72(4):325–333.
   PubMed Web of Science ®Google Scholar
• Scahill L, Sukhodolsky DG, Williams SK, et al. Public health significance of tic disorders in children and adolescents. Adv Neurol. 2005;96:240–248.
   PubMedGoogle Scholar
• Claussen AH, Bitsko RH, Holbrook JR, et al. Impact of tourette syndrome on school measures in a nationally representative sample. J Dev Behav Pediatr. 2018 May;39(4):335–342.
   PubMed Web of Science ®Google Scholar
• Storch EA, Merlo LJ, Lack C, et al. Quality of life in youth with tourette’s syndrome and chronic tic disorder. J Clin Child Adolesc Psychol. 2007 Apr–June;36(2):217–227.
   PubMed Web of Science ®Google Scholar
• Johnco C, McGuire JF, McBride NM, et al. Suicidal ideation in youth with tic disorders. J Affect Disord. 2016 Aug;200:204–211.
   PubMed Web of Science ®Google Scholar
• Storch EA, Hanks CE, Mink JW, et al. Suicidal thoughts and behaviors in children and adolescents with chronic tic disorders. Depress Anxiety. 2015 Oct;32(10):744–753.
   PubMed Web of Science ®Google Scholar
• Felling RJ, Singer HS. Neurobiology of tourette syndrome: current status and need for further investigation. J Neurosci. 2011Aug31;31(35):12387–12395. .
   PubMed Web of Science ®Google Scholar
• Pourfar M, Feigin A, Tang CC, et al. Abnormal metabolic brain networks in tourette syndrome. Neurology. 2011 Mar 15;76(11):944–952.
   PubMed Web of Science ®Google Scholar
• Braun AR, Randolph C, Stoetter B, et al. The functional neuroanatomy of tourette’s syndrome: an FDG-PET study. II: relationships between regional cerebral metabolism and associated behavioral and cognitive features of the illness. Neuropsychopharmacology. 1995 Oct;13(2):151–168.
   PubMed Web of Science ®Google Scholar
• Braun AR, Stoetter B, Randolph C, et al. The functional neuroanatomy of tourette’s syndrome: an FDG-PET study. I. Regional changes in cerebral glucose metabolism differentiating patients and controls. Neuropsychopharmacology. 1993 Dec;9(4):277–291.
   PubMed Web of Science ®Google Scholar
• Jeffries KJ, Schooler C, Schoenbach C, et al. The functional neuroanatomy of tourette’s syndrome: an FDG PET study III: functional coupling of regional cerebral metabolic rates. Neuropsychopharmacology. 2002 July;27(1):92–104.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Okun MS, Muller-Vahl K, et al. Practice guideline recommendations summary: treatment of tics in people with tourette syndrome and chronic tic disorders. Neurology. 2019 May 7;92(19):896–906.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Holler-Managan Y, Okun MS, et al. Comprehensive systematic review summary: treatment of tics in people with tourette syndrome and chronic tic disorders. Neurology. 2019 May 7;92(19):907–915.
   PubMed Web of Science ®Google Scholar
• Roessner V, Plessen KJ, Rothenberger A, et al. European clinical guidelines for tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011 Apr;20(4):173–196.
   PubMed Web of Science ®Google Scholar
• Factor SA, Burkhard PR, Caroff S, et al. Recent developments in drug-induced movement disorders: a mixed picture. Lancet Neurol. 2019 Sept;18(9):880–890.
   PubMed Web of Science ®Google Scholar
• Tschoner A, Engl J, Laimer M, et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract. 2007 Aug;61(8):1356–1370.
   PubMed Web of Science ®Google Scholar
• Yaffe D, Forrest LR, Schuldiner S. The ins and outs of vesicular monoamine transporters. J Gen Physiol. 2018 May 7;150(5):671–682.
   PubMed Web of Science ®Google Scholar
• Wimalasena K. Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry. Med Res Rev. 2011 July;31(4):483–519.
   PubMed Web of Science ®Google Scholar
• Erickson JD, Schafer MK, Bonner TI, et al. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci U S A. 1996 May 14;93(10):5166–5171.
   PubMed Web of Science ®Google Scholar
• Citrome L. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. Expert Rev Neurother. 2018;18(4):323–332.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016;17(18):2461–2470.
   PubMed Web of Science ®Google Scholar
• Ingrezza [Prescribing Information]. San Diego (CA): Neurocrine Biosciences; 2020. [cited 2021 Mar 1]. Available from: https://www.neurocrine.com/assets/INGREZZA-full-Prescribing-Information.pdf.
   Google Scholar
• Grigoriadis DE, Smith E, Hoare SR, et al. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017 Apr 12;361(3):454–461.
   Web of Science ®Google Scholar
• Harriott ND, Williams JP, Smith EB, et al. VMAT2 inhibitors and the path to Ingrezza (valbenazine). Prog Med Chem. 2018;57(1):87–111.
   PubMedGoogle Scholar
• Kilbourn MR, Lee LC, Heeg MJ, et al. Absolute configuration of (+)-alpha-dihydrotetrabenazine, an active metabolite of tetrabenazine. Chirality. 1997;9(1):59–62.
   PubMed Web of Science ®Google Scholar
• Skor H, Smith EB, Loewen G, et al. Differences in dihydrotetrabenazine isomer concentrations following administration of tetrabenazine and valbenazine. Drugs R D. 2017 Sept;17(3):449–459.
   PubMed Web of Science ®Google Scholar
• Leckman JF, Riddle MA, Hardin MT, et al. The yale global tic severity scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry. 1989 July;28(4):566–573.
   PubMed Web of Science ®Google Scholar
• O’Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord. 2015 Oct;30(12):1681–1687.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174:476–484.
   PubMed Web of Science ®Google Scholar
• Factor SA, Remington G, Comella CL, et al. The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study. J Clin Psychiatry. 2017 Nov 14;78:1344–1350.
   PubMed Web of Science ®Google Scholar
• Orap [Prescribing Information]. Sellersville (PA): Teva Pharmaceuticals USA; 2008.
   Google Scholar
• Abilify [Prescribing Information]. Tokyo, Japan: Otsuka America Pharmaceutical Inc; 2016.
   Google Scholar
• Haloperidol. 2018 [cited 2018 Oct 31]. Available from: https://www.drugs.com/monograph/haloperidol.html
   Google Scholar
• Muller-Vahl KR, Krueger D. Does Tourette syndrome prevent tardive dyskinesia? Mov Disord. 2011 Nov;26(13):2442–2443.
   PubMed Web of Science ®Google Scholar
• Niemann N, Jankovic J. Real-world experience with VMAT2 inhibitors. Clin Neuropharmacol. 2019 Mar/Apr;42(2):37–41.
   PubMed Web of Science ®Google Scholar
• Kenney CJ, Hunter CB, Mejia NI, et al. Tetrabenazine in the treatment of tourette syndrome. J Pediatr Neurol. 2007;5(1):9–13.
   Google Scholar
• Porta M, Sassi M, Cavallazzi M, et al. Tourette’s syndrome and role of tetrabenazine: review and personal experience. Clin Drug Investig. 2008;28(7):443–459.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Jimenez-Shahed J, Budman C, et al. Deutetrabenazine in tics associated with tourette syndrome. Tremor Other Hyperkinet Mov (N Y). 2016;6:422.
   PubMed Web of Science ®Google Scholar
• Teva announces registration trials of deutetrabenazine in pediatric patients with tourette syndrome did not meet the primary endpoint. Press Release, 2020 Feb 19. Available from: https://www.tevapharm.com/news-and-media/latest-news/teva-announces-registration-trials-of-deutetrabenazine-in-pediatric-patients-with-tourette-syndrome-did-n/.
   Google Scholar